Purity
Greater than 90% as determined by SDS-PAGE.
Alternative Names
EC 3.1.1.4; GIIC sPLA2; Group IIA phospholipase A2; membrane associated; Modifier of MIN 1 mouse homolog; MOM1; Non-pancreatic secretory phospholipase A2; NPS PLA2; NPS-PLA2; PA2GA_HUMAN; Phosphatidylcholine 2-acylhydrolase 2A; Phosphatidylcholine 2acylhydrolase; Phospholipase A2; Phospholipase A2 group IIA (platelets, synovial fluid); Phospholipase A2 membrane associated; Phospholipase A2 polypeptide B; Phospholipase A2 synovial; PLA2; PLA2B; PLA2G2A; PLA2L; PLA2S; PLAS1; RASF A; sPLA2
Species
Homo sapiens (Human)
Expression Region
21-144aa
Target Protein Sequence
NLVNFHRMIKLTTGKEAALSYGFYGCHCGVGGRGSPKDATDRCCVTHDCCYKRLEKRGCGTKFLSYKFSNSGSRITCAKQDSCRSQLCECDKAAATCFARNKTTYNKKYQYYSNKHCRGSTPRC
Note: The complete sequence including tag
sequence, target protein sequence and linker sequence could be provided upon request.
Protein Length
Full Length of Mature Protein
Tag Info
N-terminal 6xHis-tagged
Form
Liquid or Lyophilized powder
Note: We will preferentially ship the format that
we have in stock, however, if you have any special requirement for the format, please remark your
requirement when placing the order, we will prepare according to your demand.
Buffer
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the
glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer,
6% Trehalose, pH 8.0.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw
cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature
and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized
form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.
Description
CUSABIO transfected the expression vector which inserted the recombinant DNA into the E.coli, cultured the cells, and then induced the transcription and translation of the cloned vector. The N-terminal 6xHis tag sequence was appended to the gene coding for the E.coli of the human PLA2G2A protein to form the recombinant DNA. The recombinant human PLA2G2A was expressed as N-terminal 6xHis-tagged fusion. The purity of the protein is greater than 90% assayed by SDS-PAGE. It has an apparent molecular weight of approximately 17 kDa.
Pla2g2a has been identified as a susceptibility gene for cancer of the small and large intestine. Interestingly, unlike most previously identified tumor susceptibility genes, Pla2g2a does not behave like a classical oncogene or tumor suppressor gene. PLA2G2A was specifically expressed in lines with constitutive Wnt activity, implicating B-catenin–dependent Wnt signaling as a major upstream regulator of PLA2G2A expression. In GC, patients with tumors expressing high levels of PLA2G2A, a secreted phospholipase, have been shown to exhibit significantly improved survival compared with patients with low PLA2G2A–expressing tumors. Although PLA2G2A has been proposed as a potential tumor suppressor, evidence supporting this model is conflicting. Current studies support the notion that in addition to being a prognostic biomarker, PLA2G2A plays an intimate functional role in inhibiting GC progression. One implication of our findings is that because PLA2G2A is often underexpressed in late-stage and metastatic tumors, it is plausible that the reintroduction of PLA2G2A into aggressive tumors, by either gene therapy, administration of PLA2G2A protein, or intriguingly via epigenetic reactivation, might constitute a novel therapy for late-stage GC.